's Avatar

@damienleith.bsky.social

PhD student with an interest in the early detection of MASLD in T2D, working on the iDiabetes precision medicine platform.

52 Followers  |  69 Following  |  5 Posts  |  Joined: 18.11.2024
Posts Following

Posts by (@damienleith.bsky.social)

Our editorial published in this months JIM - @liverepi.bsky.social & colleagues identify MASLD in 18.1% of 28,000 middle-aged Swedish adults, define MASLD risk factors that translate into actionable advice for patients and identify risk with any alcohol use and possible deleterious effects of coffee

19.02.2026 16:57 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Post image

Delighted to share the evolution of @torchuk.bsky.social and our lessons learnt as a road map πŸ—ΊοΈ πŸ₯

Such a pleasure to work with talented colleagues across the UK to shape this and prime our project pipeline to improve outcomes in liver disease

doi.org/10.1136/flga...

#liversky #gastrosky #EVADE

09.02.2026 11:03 β€” πŸ‘ 3    πŸ” 2    πŸ’¬ 1    πŸ“Œ 0

Great article from Lazarus et al on the parallels today in the fight against MASLD with previous lessons learned from viral hepatitis

05.02.2026 20:44 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease Nature Reviews Gastroenterology & Hepatology, Published online: 30 January 2026; doi:10.1038/s41575-026-01174-zSteatotic liver disease (SLD), which might lead to cirrhosis and hepatocellular carcinoma, is on the rise worldwide. This Expert Recommendation draws on lessons learned to tackle viral hepatitis and proposes a framework for SLD screening and testing policies.

ICYMI: New online! Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease

05.02.2026 20:42 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 1

Our editorial in Hepatology about the FMO (fibrotic/ at-risk MASH in obesity) score. Developed to identify At-risk MASH. Validated in 4 external cohort. It uses ALT, AST, triglycerides and HDL and is able to rule-our At-risk MASH with a NPV of 0.97 and predicts LRE.
journals.lww.com/hep/citation...

15.12.2025 22:31 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

I do hope there will be a prize for the nation with the biggest percentage of it's hospitals represented!

25.11.2025 22:14 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

Traction building nicely across the πŸ‡¬πŸ‡§

Any help with spreading the word and getting hospital sites involved in your regions would be greatly appreciated πŸ™πŸΌ

We are folding in patient trajectory as a novel angle - should be interesting!

#liversky

25.11.2025 21:03 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0

Our paper published today in Frontline Gastro
18 months after introducing a decentralised Fibroscan service:
β‡’Patient: 33 564 km and 16.1 days of travel saved.
β‡’Environmental: 4929.4 kgCO2 of CO2 saved.
β‡’Hospital services: 167 hospital appointments saved (=Β£43,587).

fg.bmj.com/content/flga...

21.11.2025 11:01 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
Decompensated cirrhosis: an update of the BSG/BASL admission care bundle Acute decompensated cirrhosis (DC) and acute-on-chronic liver failure are common reasons for hospital admission that have a high in-hospital mortality rate (10%–20%). Patients require a detailed asses...

Fantastic to see the updated BSG/BASL decompensated cirrhosis admission bundle in print at FG
- practical guidance to improve care in the first 24 hours as well as implementation strategy - congrats Stuart McPherson for driving this! #livertwitter

fg.bmj.com/content/earl...

16.04.2025 18:54 β€” πŸ‘ 11    πŸ” 6    πŸ’¬ 0    πŸ“Œ 0